With over 120 issued and pending patent applications, Autonomix is building a comprehensive, global IP portfolio in nerve-sensing and modulation Newly issued patent strengthens the Company’s strategic position in a multi-billion-dollar market opportunity and unlocking potential across cardiovascular, renal, and other high-burden diseases THE WOODLANDS, TX, Oct. 09, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing ...

GLP study marks a key milestone in Autonomix's path to achieve regulatory approvals Company remains on track to submit Investigational Device Exemption (“IDE”), and if approved, commence U.S. clinical trials in 2026 to support a De Novo FDA application THE WOODLANDS, TX, Sept. 29, 2025 (GLOBE NEWSWIRE) -- Autonomix Medical, Inc. (NASDAQ: AMIX) (“Autonomix” or the “Company”), a medical device company dedicated to advancing precision nerve-targeted treatments, today announced that it has commenced a Good Labo ...

Core Viewpoint - Autonomix Medical, Inc. has initiated a Good Laboratory Practice (GLP) preclinical study for its Sensing and RF Ablation System aimed at treating pancreatic cancer pain, marking a significant step towards regulatory approval and potential clinical trials in the U.S. by 2026 [1][2][3] Company Overview - Autonomix is focused on advancing innovative medical technologies for diagnosing and treating diseases related to the nervous system, utilizing a first-in-class platform technology that includes a catheter-based microchip sensing array [6][7] - The company's technology aims to provide transvascular diagnosis and treatment of peripheral nervous system diseases, with initial development targeting pain management in pancreatic cancer [7] Regulatory Pathway - The GLP study is essential for ensuring the reliability and integrity of Autonomix's devices, which is a prerequisite for submitting data to the FDA for Investigational Device Exemption (IDE) clinical trials [2] - The company is on track to file its IDE application, with plans to commence clinical studies in the following year if approved [3] Technological Potential - Autonomix's technology has the potential to address multiple high-need therapeutic areas, including cardiology, resistant hypertension, interventional pain management, and gastrointestinal disorders [4][6] - The platform is designed to tackle a wide spectrum of diseases, indicating a broad market opportunity for the company [7]

Core Insights - Autonomix Medical, Inc. is presenting findings from its first-in-human proof-of-concept clinical trial at the 2025 CIRSE Annual Congress in Barcelona, Spain, from September 13-17, 2025 [1] - The presentation will focus on the application of artificial intelligence in interventional radiology, specifically addressing pain mitigation in pancreatic adenocarcinoma through neurolysis via transvascular radiofrequency ablation [2] Company Overview - Autonomix is a medical device company dedicated to advancing technologies for diagnosing and treating diseases of the nervous system, utilizing a catheter-based microchip sensing array for enhanced neural signal detection [4] - The company's initial focus is on treating pain associated with pancreatic cancer, a condition currently lacking reliable treatment options, with potential applications across various medical fields including cardiology and chronic pain management [5] Event Details - The presentation will be led by Marco Bedoya, VP of Research and Development, during the session titled "AI in IR: Machine Learning, SOP and Collaborative Development" on September 15, 2025, from 4:15 PM to 5:15 PM CEST [2]

Core Insights - Autonomix Medical, Inc. has announced positive results from a post hoc analysis of its proof-of-concept human clinical trial ("PoC 1"), highlighting sustained pain reduction, quality of life improvements, and 100% opioid-free outcomes [2][4] Company Overview - Autonomix is a medical device company focused on innovative technologies for diagnosing and treating diseases of the nervous system, utilizing a first-in-class catheter-based microchip sensing array [3] - The technology aims to enable transvascular diagnosis and treatment of peripheral nervous system diseases, potentially applicable across various medical fields [3][4] Technology Development - The initial focus of the technology is on pain management, particularly for pancreatic cancer, which is known for causing severe pain and lacks effective treatment options [4] - The platform technology has the potential to address multiple indications, including cardiology, hypertension, and chronic pain management [4]

Core Insights - Autonomix Medical, Inc. has reported long-term data indicating a nearly 66% reduction in pain for patients with severe pancreatic cancer pain, with a mean reduction of 5.08 on the VAS pain scale [1][7] - 100% of responders were opioid-free at the 3-month follow-up, highlighting the potential of the technology as a non-opioid alternative for pain management [2][7] - The company is expanding its proof-of-concept studies to include additional visceral cancers, indicating a broader market opportunity [3][4] Group 1: Study Results - The PoC 1 study demonstrated statistically significant pain relief as early as 24 hours post-procedure, with sustained relief lasting up to five months [3][9] - Responding patients reported a mean 76.5% improvement in global health and a 51.5% improvement in functional ability at 7 days post-procedure [7][9] - The study enrolled 20 patients, with 19 treated successfully, and showed a strong safety profile with no serious adverse events related to the procedure [11][9] Group 2: Technology and Market Potential - Autonomix's technology is a platform that could address various indications, including cardiology and chronic pain management, beyond just cancer pain [4][12] - The follow-on PoC 2 phase aims to evaluate pain management for additional visceral cancers, expanding the potential addressable market significantly [3][4] - The company's catheter-based microchip sensing array technology is designed to detect and differentiate neural signals, which may enhance treatment efficacy [10][12]

Core Insights - Autonomix Medical, Inc. is set to present at the H.C. Wainwright 27th Annual Global Investment Conference from September 8-10, 2025, in New York, NY [1] - The company focuses on innovative technologies for diagnosing and treating diseases of the nervous system, with a first-in-class platform technology that includes a catheter-based microchip sensing array [4][5] - The initial application of this technology is aimed at treating pain associated with pancreatic cancer, a condition currently lacking reliable treatment options [5] Company Overview - Autonomix Medical, Inc. specializes in medical devices that aim to revolutionize the diagnosis and treatment of nervous system diseases [4] - The company's technology is designed to detect and differentiate neural signals with greater sensitivity than existing technologies, enabling transvascular diagnosis and treatment of peripheral nervous system diseases [4] - The investigational technology has not yet received marketing clearance in the United States [5] Conference Participation - Management will be available for in-person one-on-one meetings with qualified investors registered for the conference [2] - A video webcast of the presentation will be available on-demand starting September 8, 2025, at 7:00 AM ET, and will be archived for 90 days [3]

Core Insights - Autonomix Medical, Inc. has been granted a new patent, strengthening its position in a multi-billion-dollar market for medical devices targeting cardiovascular, renal, and other high-burden diseases [1][2] Patent and Technology - The newly issued Patent No. 3,697,298 ('298 patent) relates to a medical device that captures and processes physiological signals for real-time monitoring, applicable in various fields including coronary artery mapping and neurotherapy [1][3] - The '298 patent enhances the company's competitive edge by protecting its proprietary technology, which is expected to create diverse revenue streams and expand its global presence [2][3] Technology Platform - Autonomix's technology platform features a catheter-based microchip sensing array that can detect neural signals with greater sensitivity than existing technologies, enabling precision-guided treatment for conditions like chronic pain and hypertension [4][6] - The system includes distributed signal acquisition modules that improve data integrity during neural mapping, with key elements such as miniaturization and noise reduction [3][4] Development Focus - The company is initially focusing on developing its technology for treating pancreatic cancer, a condition associated with severe pain and lacking reliable treatment options [7] - The technology has the potential to address a wide range of indications, including cardiology and chronic pain management, across various disease categories [7]

Company Overview - Autonomix Medical, Inc. is a medical device company focused on advancing precision nerve-targeted treatments [2][3] - The company is developing a first-in-class platform system technology that includes a catheter-based microchip sensing array, which aims to detect and differentiate neural signals with greater sensitivity than current technologies [3][4] Technology and Applications - The initial focus of the technology is on treating pain, particularly in pancreatic cancer, which is known for causing debilitating pain and lacks reliable treatment options [4] - The technology has the potential to address a wide range of indications, including cardiology, hypertension, and chronic pain management, across various diseases [4] Upcoming Events - The President and CEO of Autonomix, Brad Hauser, will participate in a virtual investor webinar hosted by Ladenburg Thalmann on August 21, 2025, at 1:00 PM ET [2][3] - The webinar will include a question and answer session, allowing participants to pre-submit questions [3]

Company Overview - Autonomix Medical, Inc. is a medical device company focused on advancing precision nerve-targeted treatments [3] - The company is developing a first-in-class platform system technology that includes a catheter-based microchip sensing array, which aims to detect and differentiate neural signals with greater sensitivity than current technologies [3] Technology and Applications - The initial focus of the technology is on treating pain, specifically targeting pancreatic cancer, which is known for causing debilitating pain and lacks reliable treatment options [4] - The technology has the potential to address a wide range of indications, including cardiology, hypertension, and chronic pain management, across various diseases [4] - The technology is currently investigational and has not yet received marketing clearance in the United States [4] Upcoming Events - Autonomix will present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech, scheduled for August 19-21, 2025, with the presentation taking place on August 21, 2025, at 2:20 PM ET [1]